Current Report Filing (8-k)
May 25 2022 - 01:42PM
Edgar (US Regulatory)
0001574910false00015749102022-05-202022-05-20iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange
Act of 1934
May 20,
2022
Date of Report (Date of earliest event reported)
333-188401
Commission File Number
|
RENAVOTIO,
INC.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
|
99-0385424
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(IRS Employer
Identification No.)
|
|
601 South Boulder Ave.,
Suite 600, Tulsa, OK
|
|
74119
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(888)
928-1312
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
None
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Renavotio, Inc. is referred to herein as “Renavotio”, “we”, “our”,
or “us”.
ITEM 8.01. OTHER EVENTS
On May 20, 2022, Renavotio Medical, LLC, an Oklahoma Limited
Liability Company and our wholly owned subsidiary (“Renavotio
Medical”), and Kyocera Medical Technologies, Inc , a
California corporation (“Kyocera”), completed a Reseller Agreement
between the two companies. Kyocera is in the business of 3D
designing, manufacturing, and distributing products in the trauma,
spine and orthopedic surgery areas (the “Products”).
Renavotio Medical, referred to in the Agreement as the
“Distributor”, is in the business of distributing the
Products as the Reseller in the Agreement. Pursuant to the
Agreement, Kyocera has appointed Renavotio Medical as the exclusive
distributor of the Products in the “Territory”, which is defined as
the following countries for which Renavotio will be the exclusive
distributor: Bahrain; Iraq; Kuwait; Oman; Saudi Arabia; and the
United Arab Emirates. As the exclusive distributor, Renavotio
Medical will pay the agreed to cost of products and resell to its
targeted clients as agreed in the exclusive territory
assigned to Renavotio Medical.
ITEM 9.01. FINANCIAL STATEMENTS & EXHIBITS
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL
Document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
Dated: May 25, 2022
|
By:
|
/s/ William Robinson
|
|
|
|
|
William Robinson
|
|
|
|
|
Chief Executive Officer
|
|
Renavotio (CE) (USOTC:RIII)
Historical Stock Chart
From May 2023 to Jun 2023
Renavotio (CE) (USOTC:RIII)
Historical Stock Chart
From Jun 2022 to Jun 2023
